Document Detail


Efficacy and safety of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in study participants with hypertension and diabetes: a subpopulation analysis of the TRINITY study.
MedLine Citation:
PMID:  22030597     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Most patients with hypertension and diabetes require two or more antihypertensive agents to achieve the recommended blood pressure (BP) goal of <130/80 mm Hg. This prespecified subgroup analysis from the TRIple Therapy with Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide in HyperteNsIve PatienTs StudY assessed the efficacy and safety of triple-combination treatment (olmesartan medoxomil 40/amlodipine besylate 10/hydrochlorothiazide 25 mg) versus the component dual-combination treatments according to diabetes status (diabetes; non-diabetes). METHODS: Participants received dual-combination treatment for 4 weeks or placebo for 2 weeks. Participants receiving placebo switched to dual-combination treatment from week 2 to week 4. At week 4, participants switched to triple-combination treatment or continued on dual-combination treatment until week 12. RESULTS: The prespecified changes in BP from baseline for the diabetes subgroup receiving triple-combination treatment were greater than the respective dual-combination treatments (P ≤ .0013). Also, more participants with diabetes receiving triple-combination treatment reached BP goal (<130/80 mm Hg) versus those receiving dual-combination treatments (P ≤ .0092). In a post hoc analysis, significantly greater proportions of study participants with diabetes achieved BP targets with triple-combination treatment compared with each dual-combination treatment. Most treatment-emergent adverse events were mild to moderate in severity. CONCLUSIONS: In participants with hypertension and diabetes, triple-combination treatment led to greater BP reductions and enabled greater proportions of participants to reach BP goal versus the dual-combination treatments. Triple-combination treatment was well tolerated in both diabetes and non-diabetes subgroups.
Authors:
Steven G Chrysant; Joseph L Izzo; Dean J Kereiakes; Thomas Littlejohn; Suzanne Oparil; Michael Melino; James Lee; Victor Fernandez; Reinilde Heyrman
Related Documents :
9470007 - Can cardiovascular risk be predicted by newborn, childhood, and adolescent body size? a...
382957 - Animal obesities.
10195377 - Carbohydrate-induced thermogenesis in obese women. effect of insulin and catecholamines.
18541587 - Abdominal obesity and hyperglycemia mask the effect of a common apoc3 haplotype on the ...
15220217 - Polymorphisms in type ii sh2 domain-containing inositol 5-phosphatase (inppl1, ship2) a...
17318777 - Hydroxyurea associated leg ulcer succesfully treated with hyperbaric oxygen in a diabet...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-10-25
Journal Detail:
Title:  Journal of the American Society of Hypertension : JASH     Volume:  -     ISSN:  1933-1711     ISO Abbreviation:  -     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-10-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101312518     Medline TA:  J Am Soc Hypertens     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.
Affiliation:
Oklahoma Cardiovascular and Hypertension Center and University of Oklahoma College of Medicine, Oklahoma City, OK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Learning Lumbar Spine Manipulation: The Effects of Frequency and Self-Control of Feedback.
Next Document:  Claudin-1 involved in neonatal ichthyosis - sclerosing cholangitis syndrome, regulates hepatic parac...